TrialJournal of neurology2024

Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.

Tomoo Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.